Obesity-induced metabolic diseases, including type 2 diabetes and nonalcoholic fatty liver disease, will be a defining healthcare issue of the 21st century 1 . Aside from surgical remediation, progress in the treatment of these diseases with lifestyle or pharmacologic therapies has been disappointing.
Under normal physiological conditions, activation of the nutrientsensing mTorc1 pathway, a substrate of insulin-Akt signaling 2 , stimulates hepatic de novo lipogenesis 3 . For example, treatment of hepatocytes with rapamycin, an allosteric inhibitor of mTorc1, prevents insulin activation of the lipogenic transcription factor Srebp1c (also known as Srebf1) 3, 4 , and liver-specific knockout of the mTorc1-defining component Raptor protects from diet-induced hepatosteatosis, probably as a result of reduced lipogenesis 5 . At the same time, insulin-Akt signaling also acts to repress the action of forkhead box O1 (Foxo1) to suppress hepatic gluconeogenesis 6 , defining the fasting-refeeding transition 7 . In obesity-induced hepatic insulin resistance, however, these parallel pathways become dissociated 3 . Specifically, Foxo1 action is unrestrained in the 'insulin-resistant' state to stimulate gluconeogenesis and glycogenolysis, and the resultant higher plasma insulin levels accelerate flux through the preserved Akt-mTorc1 pathway to simultaneously promote hepatic glucose production and hepatosteatosisthe latter being a correlate of cirrhosis, hepatocellular cancer and a need for liver transplantation 8 . The bifurcation of the insulin signaling pathways after Akt-to Foxo1 for glucose production and to mTorc1 and Srebp1c for lipogenesis-raises the question of whether these pathways have additional inputs. Here we explore further the role of Notch signaling in metabolic homeostasis of the liver.
Notch signaling is crucial for cell-type specification and lineage restriction 9 . Cell surface-tethered ligands (Jagged and Delta-like) bind Notch receptors on neighboring cells, resulting in a series of cleavage events that culminate in γ-secretase-dependent liberation of the Notch intracellular domain (NICD) 10 . The NICD translocates to the nucleus, where it binds to and coactivates the transcriptional effector Rbp-Jk, promoting expression of the Hes (hairy enhancer of split) and Hey (Hes-related) family of genes 11 . Homozygous null alleles of components of this signaling pathway result in embryonic lethality, demonstrating their importance in normal development [12] [13] [14] . Notch signaling is therapeutically accessible, and inhibitors are currently in advanced clinical development for cancer 15 .
The homeostatic functions of Notch in developed tissues have received less attention, with the exception of neoplastic processes 16 . We have previously shown that Notch signaling in the liver is regulated in response to metabolic stimuli and that Notch1 increases hepatic glucose production by coactivating Foxo1 at the G6pc (encoding glucose-6-phosphatase) promoter 17 . Conversely, liver-specific deletion of Rbp-Jk in mice (resulting in mice called L-Rbpj mice) or treatment with a γ-secretase inhibitor (GSI) improves glucose tolerance and reduces hepatocyte glucose production 17 . As prior studies have demonstrated that Notch1 can activate mTorc1 in leukemic cells, whereas GSIs decrease mTorc1 activity in breast cancer 18, 19 , we hypothesized that hepatic Notch can modulate the coordinate actions of insulin on gluconeogenesis (through Foxo1) and lipogenesis (through mTorc1). Indeed, we found that inhibition of hepatic Notch protects from obesity-induced fatty liver, probably through decreased de novo lipogenesis. Conversely, constitutive hepatic Notch signaling stabilizes and activates mTorc1, leading to increased lipogenesis and fatty liver. We show that Notch-mediated hepatosteatosis is rapamycin sensitive, whereas Notch-induced glucose intolerance is mTor independent. These results establish Notch as a unique pharmacological target in liver whose inhibition can prevent the twin abnormalities of hepatic insulin resistance-excessive glucose production and fatty liver-through its ability to uncouple Akt signaling from mTor activation.
RESULTS
Liver Notch activity is altered by nutrient state Notch1 activation in liver, as reflected by cleavage at Val1744 and increased expression of Notch target genes, increases with fasting 17 . When we analyzed wild-type mice after overnight fasting, we found that refeeding quickly (0-2 h) repressed Notch1 cleavage and target gene expression, but this decline was followed by a second peak of Notch activation at later time points (4-12 h) ( Fig. 1a and Supplementary Fig. 1) . Notably, Notch activation during fasting coincided with increased gluconeogenic gene expression, whereas the second peak coincided with maximal expression of Srebp1c and its transcriptional targets (Fasn (fatty acid synthase) and Acc1 (acetyl-CoA carboxylase)) ( Fig. 1b-d) , as well as activation of mTor (data not shown). Notch target gene induction was absent in livers from mice lacking hepatocyte Rbp-Jk (L-Rbpj mice) ( Fig. 1e) 17 , confirming that classical Notch activation is affected by the nutritional state.
We hypothesized that nutrient excess would similarly stimulate hepatic Notch signaling. We analyzed livers from mice fed a high-fat diet (HFD), which showed greater Notch activation than those of chow-fed littermates ( Fig. 1f,g) , as did hepatocytes and livers from leptin signaling-deficient mice as compared to those from normal mice ( Fig. 1h,i) .
These results suggest a cell-autonomous dysregulation of Notch signaling in obesity and fatty liver.
L-Rbpj mice show resistance to diet-induced fatty liver
As whole-body disruption of Rbp-Jk results in embryonic lethality 13 , we generated mice harboring a liver-specific knockout (L-Rbpj) in which hepatocyte Rbp-Jk was deleted postnatally 17 and that had full recombination by 6-12 weeks of age 20 . We have previously shown that L-Rbpj mice are protected from obesity-induced insulin resistance 17 . Given the interaction between Rbp-Jk and Foxo1 (ref. 21) , we hypothesized that L-Rbpj mice would have similarly increased hepatic triglyceride levels as mice lacking liver Foxo proteins 22, 23 . Notably, despite unchanged body weight, L-Rbpj mice showed lower HFD-induced hepatic steatosis ( Fig. 2a,b) that was due to a 30-50% reduction in hepatic triglyceride level (Fig. 2c) . The livers of L-Rbpj mice were smaller, without changes in adiposity ( Fig. 2d ) or serum lipid concentrations ( Supplementary Fig. 2) , as compared to those of Cre − control mice. Moreover, Rbp-Jk knockout prevented steatosis in mice lacking hepatic Foxo1 (Supplementary Fig. 3a ) 22 , suggesting that Notch regulates hepatic lipid deposition independently of its known coactivation of Foxo1 targets 17 .
To understand the lower hepatic triglyceride content in L-Rbpj mice, we systematically evaluated cell-autonomous and non-cell autonomous pathways that regulate hepatic triglyceride accumulation 8, 24 . Very low density lipoprotein secretion was unaltered in L-Rbpj mice ( Supplementary Fig. 3b ), as were plasma triglyceride concentrations, after olive oil gavage ( Supplementary Fig. 3c ). Liver expression of the fatty acid oxidation enzymes encoded by Acox and Cpt1a, serum ketone concentrations and β-oxidation of exogenous fatty acids in primary hepatocytes were similarly unchanged ( Supplementary Fig. 3d-f ). Next we studied lipogenesis and found that the livers of L-Rbpj mice showed lower expression of Fasn and Acc1 compared to those of Cre − control mice ( Fig. 2e) , leading to less fatty acid synthesis ( Fig. 2f) . In primary hepatocytes derived from L-Rbpj mice, we found impaired insulin-dependent Srebp1c expression and activity as assessed by lower expression of Fasn promoterdriven luciferase containing a consensus Srebp1c binding site 25 (Fig. 2g,h) . Alternative lipogenic pathways, including peroxisome proliferator activated receptor γ (Ppar-γ) signaling 26 , were unaltered in L-Rbpj mice (Supplementary Fig. 3g ). We observed a similar protection from insulin resistance associated with lower hepatic triglyceride concentrations after short-term HFD feeding ( Supplementary Fig. 4) . These data indicate that blocking hepatic Notch reduces hepatic triglyceride concentrations, probably because of impaired Srebp1c-mediated lipogenesis.
We next studied two pathways that converge on Srebp1c: the insulin-Akt pathway and the nutrient-mTorc1 pathway 3 . Livers of L-Rbpj mice show higher insulin sensitivity with higher Akt phosphorylation at the Pdk1 site, Thr308 (ref. 17) . Conversely, we noted repressed mTorc1 signaling, as indicated by lower phosphorylation of the mTor and mTorc1 targets, p70 S6 kinase (S6k) and 4e-bp1, after either 5 h or 16 h of fasting as compared to Cre − control mice ( Fig. 2i and data not shown) [27] [28] [29] . To determine whether this effect was cell autonomous, we isolated primary hepatocytes from Cre − and L-Rbpj mice and found that although Akt phosphorylation was higher in the hepatocytes from the L-Rbpj mice (data not shown), basal and insulin-stimulated p70 S6k phosphorylation were repressed ( Fig. 2j) . These data suggest that Notch is required for maximal hepatocyte mTorc1 activity.
Notch1 decoy reduces insulin resistance and fatty liver
To exclude the possibility of a developmental phenotype in L-Rbpj mice, we transduced adult mice with a Notch1 receptor that encodes only the extracellular domain 30, 31 and acts in a dominant-negative manner by sequestering endogenous ligands. This adenovirus-driven Notch1 decoy is preferentially expressed in the liver, blocks hepatic Notch target gene expression and is poorly secreted into the circulation (data not shown). Consistent with the results from the L-Rbpj mice, expression of the Notch1 decoy in HFD-fed mice lowered glucose and insulin concentrations ( Fig. 3a,b) , liver weight and triglyceride content as compared to Cre − control mice (Fig. 3c,d ) without affecting body or adipose weight ( Supplementary Fig. 5a,b) . We next tested whether acute inhibition of Notch signaling can protect from diet-induced fatty liver and reduce mTorc1 function commensurate with that in L-Rbpj mice. Notch1 decoy inhibited Srebp1c cleavage and the expression of Fasn and Acc1 (Fig. 3e) but did not affect fatty acid oxidation (Fig. 3f) or serum lipid concentrations ( Supplementary Fig. 5c,d) . Notch1 decoy-transduced primary hepatocytes from wild-type mice similarly showed lower Srebp1c expression, as compared to hepatocytes transduced with control virus (Fig. 3g) , but no change in the expression of Pparg or its targets (Supplementary Fig. 5e ). Livers from Notch1 decoy-transduced mice demonstrated higher phosphorylation of Akt (pAkt) at Thr308 but lower pS6k at Ser389 (Fig. 3h) . Thus, similar to the results in L-Rbpj mice, acute reduction in hepatic Notch signaling increases insulin sensitivity while simultaneously lowering mTorc1-mediated Srebp1c activity and hepatic triglyceride concentrations.
Hepatic Notch1 induces mTorc1 signaling and fatty liver
Our loss-of-function studies suggest that Notch signaling is permissive for mTorc1 activation and diet-induced steatosis. We thus tested whether Notch gain of function would be sufficient to induce fatty liver in vivo. Chow-fed mice transduced with an adenovirus encoding constitutively active Notch1 (N1-IC) showed higher liver weight and triglyceride levels than mice transduced with control (GFP) adenovirus (Fig. 4a-c) without concomitant changes in body weight or composition (data not shown). Livers from N1-IC adenovirustransduced mice had higher Srebp1c cleavage, resulting in increased expression of Srebp1c and Fasn (Fig. 4d,e) . Consequently, primary hepatocytes from mice transduced with the N1-IC adenovirus showed greater lipogenesis (Supplementary Fig. 6a) . Notably, N1-IC expression did not alter lipogenic gene expression or hepatic triglyceride levels in L-Rbpj mice and hepatocytes or affect fatty-acid synthesis in hepatocytes derived from L-Rbpj mice (Fig. 4f,g and Supplementary  Fig. 6b ), suggesting that Notch-induced lipogenesis requires Rbp-Jk, which is similar to its activation of hepatic glucose production 17 .
Notch-induced lipogenic gene expression paralleled higher hepatic mTorc1 activity in fasted and, more markedly, refed mice (Fig. 4h) , which is consistent with enhanced physiologic regulation of mTorc1. In hepatoma cells and mouse primary hepatocytes, activation of mTorc1 signaling by insulin and amino acids was potentiated by N1-IC ( Fig. 4i) , resulting in Srebp1c cleavage and activation ( Fig. 4j  and Supplementary Fig. 6c ). These data suggest that Notch modulates, but does not over-ride, endogenous mTor regulation in a cellautonomous manner.
Inhibition of mTor prevents Notch-induced fatty liver
To test the hypothesis that Notch induction of lipogenic gene expression and fatty liver requires mTorc1 signaling, we cotransfected hepatoma cells with Fasn-luciferase and shRNA to Raptor 32 , the defining component of the mTorc1 complex, and then transduced the cells with the N1-IC adenovirus. Notch-induction of Fasn-luciferase activity was potentiated by insulin but was reversed by Raptor knockdown or treatment with rapamycin ( Fig. 5a and Supplementary  Fig. 7) . Similarly, Notch induction of endogenous Fasn in primary hepatocytes was augmented by insulin and suppressed by rapamycin ( Fig. 5b) , suggesting that N1-IC-induced Fasn expression is mTorc1 dependent.
On the basis of these data, we hypothesized that the higher lipogenic gene expression and fatty liver in mice transduced with N1-IC adenovirus would be ameliorated by rapamycin treatment. Indeed, Notch-mediated hepatic steatosis was completely reversed by rapamycin treatment (Fig. 5c) . The effect of rapamycin was specific to Notch induction of lipogenic genes, as Heyl and Hey1 were unaffected (Fig. 5d) . Similarly, although rapamycin induced mild glucose intolerance (data not shown) 33 , N1-IC adenovirus-transduced mice showed further exacerbation of glucose intolerance (Fig. 5e,f) . These data show that Notch-induced hepatic steatosis, but not hyperglycemia, is prevented by mTor inhibition.
Notch increases mTorc1 complex stability
To study the mechanism of altered Notch-induced mTorc1 activation, we examined mTor component expression in livers of HFD-fed L-Rbpj mice. We found unchanged levels of the shared mTorc1 and mTorc2 components, mTor and Gβl, and the mTorc2-specific component Rictor but a reduction in the levels of Raptor protein (Fig. 6a ) independent of changes in Raptor mRNA levels (data not shown), npg suggesting that the effects of Rbp-Jk deficiency on Raptor are posttranscriptional. Conversely, mice transduced with N1-IC adenovirus demonstrated higher liver Raptor protein expression as compared to control mice transduced with GFP adenovirus (Fig. 6b) . We found a similar increase in the amount of endogenous Raptor protein in hepatoma cells (Fig. 6c ) and primary hepatocytes (data not shown) from mice transduced with the N1-IC adenovirus without changes in Raptor mRNA levels (Supplementary Fig. 8a) . Transient transfection of Raptor cDNA in primary hepatocytes showed a similar effect, demonstrating that the action of Notch is independent of locus npg effects (Supplementary Fig. 8b) . Notably, the effect of N1-IC was not recapitulated by proteosomal inhibition with MG132 ( Fig. 6c) but was reversed by treatment of hepatocytes with the protein synthesis inhibitor cycloheximide (Fig. 6d) .
Raptor overexpression was insufficient to induce Fasn-luciferase, whereas coexpression of N1-IC and Raptor produced a synergistic effect (Fig. 6e) , which is consistent with previous work that Raptor overexpression does not increase mTorc1 function per se 34 . Likewise, overexpression of Raptor was insufficient to activate mTorc1 in either primary hepatocytes or HEK293 cells (data not shown). We conclude that Notch induction of Raptor expression parallels but does not cause increased mTorc1 activation and hypothesize that increased Raptor expression is secondary to higher mTorc1 complex stability. Indeed, we found that Notch overexpression increased the association among mTorc1 components in HEK293 cells (Fig. 6f ) regardless of whether Raptor (Supplementary Fig. 8c ) or mTor (Supplementary Fig. 8d ) was immunoprecipitated. We observed similar mTorc1 stabilization in FAO hepatoma cells (Supplementary Fig. 8e ) and mouse primary hepatocytes (Fig. 6g) . In addition, Notch-stabilized mTorc1 complexes were resistant to increasing concentrations of CHAPS detergent, which is known to disrupt the mTor-Raptor interaction (Supplementary Fig. 8f) [34] [35] [36] . These data indicate that Notch stabilizes and activates mTorc1, resulting in increased de novo lipogenesis and fatty liver.
DISCUSSION
The role of developmental pathways in the metabolic homeostasis of adult tissues is only beginning to be appreciated 17, 37 . We have shown that genetic or pharmacologic inhibition of Notch protects from dietinduced glucose intolerance in a Foxo1-dependent manner without effects on body weight or adiposity 17 . We demonstrate here a similar protection from fatty liver with inhibition of hepatic Notch signaling. We did not expect this result, as inhibition of hepatic Foxo1 is associated with increased hepatic lipid deposition 22, 23, 38 , an effect of shifting hepatic carbon flux from glucose to lipid production, as has been seen in other recently described mouse models 39, 40 . In this regard, it seems that chronic (as in L-Rbpj mice) or acute (using Notch decoy) Notch inhibition achieves the long-sought goal of decreasing hepatic glucose production without compensatory increases in hepatic lipid content. Notably, GSIs induce fatty liver, but they do so in a Notch-independent fashion (U.B.P., unpublished data), which is consistent with the idea that substrates of γ-secretase include Notch-unrelated pathways and restricts the repertoire of therapeutically viable Notch inhibitors that can be pursued for treatment of metabolic disease. Nonetheless, the many potential benefits of Notch inhibition, which include the amelioration of atherosclerosis 41 , provide a strong rationale to pursue Notch inhibition as a treatment of the metabolic syndrome 42 .
The identification of Notch as a regulator of carbon flux toward hepatic glucose or lipid production (Fig. 6h) is a conceptual advance, as is the finding that a molecular pathway thought to be specialized toward differentiation is regulated by physiologic (fasting and refeeding), as well as pathologic (insulin resistance), metabolic cues in hepatocytes. We hypothesize that in the overfed and insulin-resistant state, Notch signaling is inappropriately activated and reprises its developmental interactions with Foxo1 and mTorc1. The mechanisms underlying nutritional activation of hepatic Notch require further clarification. For example, it should be determined whether Notch activation in the hepatocyte requires input from neighboring hepatocytes or other resident liver cells (for example, endothelial, stellate or Kupffer cells, among others). Similarly, which of the five Notch ligands drives signaling in response to nutrients is unknown, and the possibility that different ligands signal in different metabolic states to direct carbon flux or drive differentiation is teleologically attractive.
Besides the further validation of hepatic Notch as a therapeutic target, our data demonstrate a physiologic, and potentially pharmacologic, means of regulating mTorc1 activity and lipogenesis. Previous studies have indicated that tight control of hepatic mTorc1 signaling is crucial for hepatic lipid metabolism 43, 44 . The tandem, but not necessarily related, findings of mTorc1 stabilization and activation by Notch deserve further study. Since the identification of Raptor as the npg mTorc1-regulatory subunit, it has been known that the mTor-Raptor association is sensitive to detergent concentrations 38 ; subsequent reports have confirmed this finding and identified potential posttranslational modifications of Raptor 35, 36, 45 , but none of these modifications has been shown to mediate the mTor-Raptor interaction. How Notch induces mTorc1 stability is unknown, but the demonstration that Raptor protein, but not mRNA, expression is decreased in L-Rbpj mice and that cycloheximide prevents Notch-induced stabilization indicates that a transcriptional target(s) of Notch regulates complex stability.
In summary, Notch antagonism uncouples Akt from mTor activation, suggesting that Notch antagonists from oncology and neuroscience 46, 47 may be repurposed to treat fatty liver and diabetes. Furthermore, as Notch-mediated mTorc1 activation does not seem to be cell-type specific, modulators of mTorc1 processing and degradation may be a therapeutic avenue to block mTorc1 activity without the metabolic liabilities of current mTor inhibitors 33, 48 .
METHODS
Methods and any associated references are available in the online version of the paper.
